OR
ORIC
Methodology breakdown computing — it will appear here on its own.
ORIC Pharmaceuticals Inc (ORIC) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for ORIC — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.50 | NEUTRAL |
| Stochastic %K (14) | 13.15 | BUY |
| CCI (20) | -125.76 | BUY |
| Williams %R (14) | -86.85 | BUY |
| MACD (12,26,9) | -0.24 | SELL |
| ROC (10) | -10.19 | SELL |
| Momentum (10) | -1.40 | SELL |
| EMA (10) | 12.72 | SELL |
| SMA (10) | 12.74 | SELL |
| EMA (20) | 12.89 | SELL |
| SMA (20) | 13.31 | SELL |
| EMA (30) | 12.75 | SELL |
| SMA (30) | 13.18 | SELL |
| EMA (50) | 12.27 | BUY |
| SMA (50) | 12.34 | BUY |
| EMA (100) | 11.53 | BUY |
| SMA (100) | 10.63 | BUY |
| EMA (200) | 11.38 | BUY |
| SMA (200) | 10.68 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About ORIC Pharmaceuticals Inc
Healthcare · Biotechnology
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-08-04
🟡 BULLISH LEAN
The main driver: RSI in healthy zone, Wall Street broadly bullish. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert ORIC [level]` to catch the entry, or `!plan ORIC` to size small.
Scores: 3 bullish / 3 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 4 sells
Recent: Heyman Richard A. sold 212772 sh @ $12.00 (2026-07-06); Heyman Richard A. sold 206672 sh @ $12.02 (2026-07-24); Piscitelli Dominic sold 69828 sh @ $13.69 (2026-08-26)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.